Our COVID-19 Research

Tackling Challenges from Many Angles

Geneva is well-positioned to continue the fight against COVID-19. As a leading organization that drives military medical research around the world, Geneva is grounded in experience with a 27-year history of success. Using knowledge gained from research addressing global infectious disease threats, our infectious disease research – combined with our scientific and technical program management expertise – puts Geneva in a unique position to advance COVID-19 research.

VACCINE DEVELOPMENT

Clinical Trials

Geneva is advancing phase 3 clinical trials for two COVID-19 vaccines at six military treatment facilities under Operation Warp Speed – COVID-19 Response Operation and supporting additional trials for studies under NIH-sponsored ACTIV-2 and ACTIV-4 master protocols to speed the development of the most promising COVID treatments and vaccines.

NOVEL THERAPEUTICS

Monoclonal Antibodies

Using human monoclonal antibodies isolated from survivors, Geneva researchers are advancing promising new treatments for COVID-19 and advancing novel applications to minimize viral replication.

RAPID DIAGNOSTICS

Biosurveillance

Leveraging technology capabilties, Geneva researchers are developing a multiplex remote system for biosurveillance to diagnose viruses, including SARS-CoV-2, using a readily-available smartphone.

COUNTERMEASURES

Treatment of Co-Morbidities

Geneva researchers are studying ways to limit the duration of patients suffering from acute respiratory distress syndrome (ARDS) caused by COVID-19, contributing to post-COVID best practices, and understanding how the virus is passed in placenta from the mother to baby before and at birth.

Featured Program

USING TELEMEDICINE TO BRING CRITICAL CARE SUPPORT TO EVERY BEDSIDE

Under the National Emergency Tele-Critical Care Network project (NETCCN), Geneva researchers are helping to address a critical problem for COVID healthcare: the shortage of critical care trained clinicians. NETCCN is an evolving network of clinical care teams that provide expert medical advice to anyone who needs it, wherever they may be, using network-enabled mobile devices.

Learn more about NETCCN

Case Study

Operation Warp Speed

Operation Warp Speed and the multi-agency initiative’s central goal – to develop, produce, and distribute 300 million doses of a safe and effective coronavirus vaccine by January 2021 – requires a deep knowledge of science and how to manage complex government operations while navigating a challenging pandemic.

In August 2020, prime contract research organization (CRO) Pharm-Olam and Geneva were selected by the U.S. Department of Defense (DoD) to support phase 3 clinical trials for two vaccine candidates.

GENEVA’S ROLES

• Clinical trials management at military treatment facilities (MTFs)
• Regulatory expertise
• Scientific expertise
• Recruitment of highly skilled medical and technical personnel
• Facilitating the rapid acceleration of research timelines

Geneva employs 116 employees across the U.S. supporting OWS with 1,720 total participants enrolled across six military treatment facilities nationwide.

DOWNLOAD THE CASE STUDY